Alumis’ (ALMS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Alumis (NASDAQ:ALMS) in a research report sent to investors on Wednesday morning,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the stock. HC Wainwright also issued estimates for Alumis’ Q1 2025 earnings at ($1.29) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at ($1.01) EPS and FY2025 earnings at ($4.26) EPS.

A number of other equities research analysts have also issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, March 20th. Oppenheimer started coverage on shares of Alumis in a research report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $26.00.

Alumis Stock Up 23.0 %

Shares of Alumis stock opened at $4.92 on Wednesday. The company has a fifty day moving average price of $5.49 and a 200 day moving average price of $8.40. Alumis has a twelve month low of $3.18 and a twelve month high of $13.53.

Hedge Funds Weigh In On Alumis

A number of institutional investors have recently made changes to their positions in ALMS. Geode Capital Management LLC acquired a new stake in Alumis in the third quarter valued at $3,266,000. State Street Corp bought a new stake in shares of Alumis in the 3rd quarter worth about $866,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Alumis in the 3rd quarter valued at about $1,160,000. Stifel Financial Corp bought a new position in shares of Alumis during the third quarter worth about $931,000. Finally, Barclays PLC acquired a new position in Alumis in the third quarter worth about $197,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.